Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Covington
Queensland Health
McKinsey
Julphar
Chinese Patent Office
Accenture
QuintilesIMS
UBS
Federal Trade Commission

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 7,919,461 protect, and when does it expire?


Patent ► Subscribe protects OMONTYS and OMONTYS PRESERVATIVE FREE and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.

Summary for Patent: ► Subscribe

Title:Erythropoietin receptor peptide formulations and uses
Abstract: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Inventor(s): Duliege; Anne-Marie (Palo Alto, CA), Stead; Richard (Bellevue, WA), Leuther; Kerstin (San Jose, CA), Woodburn; Kathryn Wynne (Campbell, CA), Naso; Robert Barnett (Menlo Park, CA)
Assignee: Affymax, Inc. (Palo Alto, CA)
Application Number:11/777,500
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-007Mar 27, 2012DISCNNoNo► Subscribe► Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Takeda Pharms Usa
OMONTYS
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-008Mar 27, 2012DISCNNoNo► Subscribe► Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-001Mar 27, 2012DISCNNoNo► Subscribe► Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-002Mar 27, 2012DISCNNoNo► Subscribe► Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
Takeda Pharms Usa
OMONTYS PRESERVATIVE FREE
peginesatide acetate
SOLUTION;INTRAVENOUS, SUBCUTANEOUS202799-003Mar 27, 2012DISCNNoNo► Subscribe► Subscribe TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,550,433Erythropoietin receptor peptide formulations and uses► Subscribe
8,324,159Erythropoietin receptor peptide formulations and uses► Subscribe
7,906,485Erythropoietin receptor peptide formulations and uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006255081► Subscribe
BrazilPI0613233► Subscribe
Canada2609401► Subscribe
China101553242► Subscribe
Costa Rica9570► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
QuintilesIMS
Cerilliant
US Army
Dow
Fuji
Johnson and Johnson
Queensland Health
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot